港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

诺诚健华

成交量：- -

成交额：- -

市值：- -

市盈率：- -

高：- -

开：- -

低：- -

收：- -

52周最高：- -

52周最低：- -

股本：2.25亿

香港流通股本：2,503.40万

量比：- -

换手率：- -

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

市销率: - -

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

诺诚健华：公司新药奥布替尼获批在国内开展临床II期研究

港股异动 | 诺诚健华-B(09969)涨超7% 奥布替尼获国家药监局批准开展治疗多发

金融界网站

诺诚健华－Ｂ(09969-HK)涨8.85%

诺诚健华奥布替尼获国家药监局批准开展治疗多发性硬化临床II期研究

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/90009"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"90009","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"90009\",,,,,undefined,":{"symbol":"90009","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":0,"timestamp":1771214400000,"preClose":0,"halted":9,"volume":0,"delay":0,"floatShares":25034000,"shares":225290000,"eps":0,"marketStatus":"农历年初二休市","change":0,"latestTime":"02-16 12:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771551000000},"marketStatusCode":7,"adr":0,"listingDate":1584892800000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1771205400000,1771214400000]],"volumeRatio":0,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":24.2,"timestamp":1770966000000,"preClose":24.38,"halted":0,"volume":6751600,"delay":0,"premium":"-100.00"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"90009\",,,,,undefined,":{"symbol":"90009","floatShares":25034000,"roa":"--","roe":"--","lyrEps":0,"shares":225290000,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/90009\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"90009\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"90009\",market:\"HK\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"90009\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2127072585","title":"诺诚健华：公司新药奥布替尼获批在国内开展临床II期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2127072585","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2127072585?lang=zh_cn&edition=fundamental","pubTime":"2021-04-15 09:25","pubTimestamp":1618449900,"startTime":"0","endTime":"0","summary":"【诺诚健华：公司新药奥布替尼获批在国内开展临床II期研究】4月14日，诺诚健华宣布，公司旗下布鲁顿酪氨酸激酶（BTK）抑制剂奥布替尼用于治疗多发性硬化（MS）已经通过中国国家药品监督管理局（NMPA）...","market":"us","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hk.eastmoney.com/a/202104151885438464.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","90009"],"gpt_icon":0},{"id":"2127252770","title":"港股异动 | 诺诚健华-B(09969)涨超7% 奥布替尼获国家药监局批准开展治疗多发","url":"https://stock-news.laohu8.com/highlight/detail?id=2127252770","media":"金融界网站","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2127252770?lang=zh_cn&edition=fundamental","pubTime":"2021-04-14 15:41","pubTimestamp":1618386116,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺诚健华-B宣布，公司旗下布鲁顿酪氨酸激酶抑制剂奥布替尼用于治疗多发性硬化已经通过中国国家药品监督管理局的临床研究用新药审评，获批在中国开展临床II期研究。截至发稿，诺诚健华涨7.03%，报20.55港元，成交额1.99亿港元。2020年11月，奥布替尼获美国FDA批准开展治疗多发性硬化临床II期研究。","market":"hk","thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hk.jrj.com.cn/2021/04/14154132371805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["90009","09969"],"gpt_icon":0},{"id":"2127047291","title":"诺诚健华－Ｂ(09969-HK)涨8.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2127047291","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2127047291?lang=zh_cn&edition=fundamental","pubTime":"2021-04-14 13:42","pubTimestamp":1618378920,"startTime":"0","endTime":"0","summary":"诺诚健华-B(09969-HK)截至13:41上涨8.85%，现报20.9港元，涨1.7港元。成交518万股，涉资1.054亿元。","market":"hk","thumbnail":"https://static.tigerbbs.com/15e20574f8fb568333181d61bb200086","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/15e20574f8fb568333181d61bb200086"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202104141884108958.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["90009","09969"],"gpt_icon":0},{"id":"2127047898","title":"诺诚健华奥布替尼获国家药监局批准开展治疗多发性硬化临床II期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2127047898","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2127047898?lang=zh_cn&edition=fundamental","pubTime":"2021-04-14 09:37","pubTimestamp":1618364220,"startTime":"0","endTime":"0","summary":"2020年11月，奥布替尼获美国FDA批准开展治疗多发性硬化临床II期研究。奥布替尼是诺诚健华自主研发的具高度靶标选择性的新型BTK抑制剂，可用于治疗自身免疫性疾病，目前正在中国及美国进行多中心、多适应症的临床试验，显示了良好的靶点占有率和安全性。现有多个新药产品处于商业化、临床及临床前研发阶段。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-04-14/doc-ikmyaawa9565055.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-04-14/doc-ikmyaawa9565055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["90009","09969"],"gpt_icon":0}],"pageSize":4,"totalPage":18,"pageCount":1,"totalSize":69,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/90009\",params:#limit:6,delay:false,,,undefined,":[]}}